Cancer最新文献

{"title":"Recent advances in gynecologic radiation oncology","authors":"Christina C. Huang MD, MS,&nbsp;Diandra N. Ayala-Peacock MD,&nbsp;Sarah J. Stephens MD,&nbsp;Junzo P. Chino MD","doi":"10.1002/cncr.35888","DOIUrl":"https://doi.org/10.1002/cncr.35888","url":null,"abstract":"<p>Significant advances have been made in the treatment of patients with gynecologic malignancies in the past few years. Integration of molecular testing in endometrial cancer now allows for more accurate risk stratification and personalized treatment recommendations for patients, with PORTEC-4a investigating outcomes after treatment de-escalation based on molecular subgroup. In several clinical trials, mismatch repair-deficiency (MMR-d) status has been proven to be a strong predictor for response to immunotherapy in the advanced/metastatic setting, and the role of immunotherapy in early-stage endometrial cancer is now being investigated. For patients with locally advanced cervical cancer, results from INTERLACE demonstrate that induction chemotherapy is now a viable treatment option, and KEYNOTE A-18 shows promise for the addition of concurrent and maintenance pembrolizumab to chemoradiation. Meanwhile, EMBRACE 1 and 2 have demonstrated the benefits of high-quality image guided brachytherapy, providing patients with locally advanced cervical cancer excellent control with improved toxicity. For patients with vulvar cancer, GOG279 demonstrated that addition of multi-agent chemotherapy with intensity modulated radiation therapy resulted in high rates of complete pathologic response, and GROINS-V III is currently investigating the role of chemotherapy and nodal radiation for patients with macrometastases on sentinel lymph node biopsy. This work summarizes the findings of recent landmark trials in endometrial, cervical, and vulvar cancer and their implications for the radiation oncologist.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 9","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143897218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Top advances of the year: Neoadjuvant immunotherapy in melanoma","authors":"Monica F. Chen MD,&nbsp;Michael A. Postow MD","doi":"10.1002/cncr.35877","DOIUrl":"https://doi.org/10.1002/cncr.35877","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 9","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143892807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating structural inequities in area-level socioeconomic and health care access measures among people with HIV and cancer (2004–2020)","authors":"Jessica Y. Islam PhD, MPH,&nbsp;Gita Suneja MD, MS,&nbsp;Yu Chen Lin PhD,&nbsp;Jennifer K. McGee-Avila PhD, MPH,&nbsp;Kea Turner PhD,&nbsp;Amir Alishahi Tabriz MD, PhD, MPH,&nbsp;Susan T. Vadaparampil PhD,&nbsp;Gypsyamber D’Souza PhD, MPH,&nbsp;M. Reuel Friedman PhD,&nbsp;Yi Guo PhD,&nbsp;Marlene Camacho-Rivera ScD, MPH, MS","doi":"10.1002/cncr.35881","DOIUrl":"https://doi.org/10.1002/cncr.35881","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>People with HIV (PWH) are less likely to receive cancer treatment compared to those without HIV. The objective of this study was to evaluate the role of area-level social determinants of health (SDoH) in cancer treatment receipt among PWH and cancer in the United States.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors used the National Cancer Database (NCDB; 2004–2020) and included adult patients (18–89 years) with HIV, identified via <i>International Classification of Diseases</i> (<i>ICD</i>)-<i>9</i> and <i>ICD</i>-<i>10</i> codes. We focused on the 14 most common cancers common among PWH. The primary outcome was receipt of first-line curative cancer treatment as documented by NCDB. Key SDoH exposures were area-level educational attainment (percent of adults without a high school degree) and income (median income quartiles) by zip code. Hierarchical multivariable logistic regression models, clustered by cancer treatment facility, were used to estimate adjusted odds ratios (aORs) with 95% confidence intervals (CIs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The authors included 31,549 people with HIV and cancer, 16.5% of whom did not receive first-line curative cancer treatment. Overall, 43% were ≥60 years old, 38% were non-Hispanic Black, 68% were male, and 39% resided in the Southern United States. The most common cancers were lung (21%), diffuse large B-cell lymphoma or DLBCL (12%), colorectal (9%), and prostate (9%). PWH living in areas of lowest educational attainment (quartile [Q]4 vs. Q1: aOR, 0.73; 95% CI, 0.66–0.82) and lowest-income (Q4 vs. Q1: aOR, 0.73; 95% CI, 0.65–0.81) areas were less likely to receive cancer treatment, after adjusting for age, sex, stage, year, and cancer type.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Area-level SDoH are associated with cancer treatment receipt among PWH, suggesting structural factors may impact this long-standing observed inequity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 9","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143892806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of neighborhood archetypes on overall mortality among young patients with acute leukemia in California","authors":"Lena E. Winestone MD, MSHP,&nbsp;Juan Yang MS,&nbsp;Tanushree Banerjee PhD,&nbsp;Meera Sangaramoorthy MS,&nbsp;Justine Kahn MD, MS,&nbsp;Renata Abrahão MD, MSc, PhD,&nbsp;Theresa H. Keegan PhD, MS,&nbsp;Iona Cheng PhD, MPH,&nbsp;Scarlett Lin Gomez MPH, PhD,&nbsp;Salma Shariff-Marco PhD, MPH","doi":"10.1002/cncr.35863","DOIUrl":"https://doi.org/10.1002/cncr.35863","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Residence in lower socioeconomic neighborhoods is associated with lower survival in children, adolescents, and young adults with leukemia. We sought to evaluate the impact of neighborhood archetypes on acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients aged 0 to 39 years diagnosed with ALL or AML from 2006 through 2016 in the California Cancer Registry were included. Nine-class neighborhood archetypes, generated by latent class analysis of 39 social and built environment attributes at the census tract level, were the primary exposure of interest. Cox proportional hazards models were used for statistical analyses, stratified by age.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 8776 patients, 72% had ALL and 28% had AML. For ALL, increased risk of mortality was observed in mixed socioeconomic status suburbs (adjusted hazard ratio, 1.39; 95% CI, 1.06–1.84) and Hispanic small towns (adjusted hazard ratio, 1.33; 95% CI, 1.03–1.84) relative to upper middle-class suburbs. For AML, neighborhood archetypes were not associated with mortality. When stratified by age, we observed associations between neighborhood archetypes (mixed socioeconomic status class suburb, inner city, Hispanic small towns) and mortality in pediatric but not young adult ALL patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings demonstrate that neighborhood archetypes efficiently account for complex interactions across social and built environment attributes with leukemia survival. The greater effects of neighborhood archetype in pediatric ALL survival, as compared to AML, may be related to the prolonged, outpatient nature of ALL maintenance therapy and the challenges associated with treatment adherence among patients residing in disadvantaged neighborhoods.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 9","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35863","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence–driven microsatellite instability profiling reveals distinctive genetic features in patients with lung cancer","authors":"Quentin Dominique Thomas MD,&nbsp;Julie Adèle Vendrell PhD,&nbsp;Lakhdar Khellaf MD,&nbsp;Sarah Cavaillon MD,&nbsp;Xavier Quantin MD, PhD,&nbsp;Jérôme Solassol MD, PhD,&nbsp;Simon Cabello-Aguilar PhD","doi":"10.1002/cncr.35882","DOIUrl":"https://doi.org/10.1002/cncr.35882","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Microsatellite instability (MSI) has emerged as a predictive biomarker for immunotherapy response in various cancers, but its role in non–small cell lung cancer (NSCLC) is not fully understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors used the bioinformatics tool MIAmS to assess microsatellite status from next-generation sequencing (NGS) data using a tailored microsatellite score. Immunohistochemistry (IHC) assays were also performed to evaluate the correspondence between MSI and deficient mismatch repair (dMMR) status. A retrospective analysis of 1547 lung cancer patients was conducted, focusing on those with an MSI phenotype. Clinical characteristics, co-occurring molecular alterations, tumor mutation burden (TMB), and homologous recombination deficiency (HRD) status were evaluated in this subset.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 1547 patients analyzed, eight (0.52%) were identified as having MSI through MIAmS, with six (0.39%) of these cases also being dMMR on IHC. All patients with dMMR had an MS score ≥2 and a history of smoking. Most patients showed loss of MLH1 and PMS2 staining on IHC. No correlation was found between MSI status and programmed death-ligand 1 expression, although all MSI patients exhibited high TMB, averaging 21.4 ± 5.6 mutations per megabase.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>MSI/dMMR in lung cancer is exceedingly rare, affecting less than 1% of cases. NGS-based analysis combined with bioinformatics tools provides a robust method to identify MSI/dMMR patients, potentially guiding immunotherapy decisions. This comprehensive approach integrates molecular genotyping and MSI detection, offering personalized treatment options for lung cancer patients. NGS-based MSI testing is emerging as the preferred method for detecting microsatellite instability in various tumor types, including rare cancers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 9","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35882","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143883893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A framework-based guide for adapting and implementing primary care–based pediatric interventions to the pediatric oncology setting: HPV PROTECT as an exemplar","authors":"James L. Klosky PhD, ABPP,&nbsp;Brooke Cherven PhD, RN, MPH,&nbsp;Melissa B. Gilkey PhD,&nbsp;Jamie Aye MD,&nbsp;Sharon M. Castellino MD, MSc,&nbsp;Maria M. Gramatges MD, PhD,&nbsp;Susan Lindemulder MD, MCR,&nbsp;Thomas B. Russell MD,&nbsp;Lucie M. Turcotte MD, MPH, MS,&nbsp;Paula D. Campos González BA,&nbsp;K. Elizabeth Skipper BSN, RN,&nbsp;Veronica Chollette MSN, RN,&nbsp;Sandra A. Mitchell PhD, CRNP,&nbsp;Graham A. Colditz MD, DrPH,&nbsp;Smita Bhatia MD MPH,&nbsp;Wendy Landier PhD, CRNP","doi":"10.1002/cncr.35857","DOIUrl":"https://doi.org/10.1002/cncr.35857","url":null,"abstract":"<p>Pediatric oncology providers can help childhood cancer survivors protect their health by ensuring they receive routine preventive services. Management of these services by survivorship providers is necessary due to patients’ suboptimal rates of re-engaging with pediatric primary care after treatment completion. This is especially the case with cancer prevention interventions, like human papillomavirus (HPV) vaccination, as survivors have greater confidence in the recommendations offered by their oncology versus primary care providers when counseling of this nature occurs. As these preventive pediatric interventions have traditionally been tested and delivered in primary care, they may lack appropriate tailoring or adaptation to the pediatric oncology setting. This article serves as a guide for using a best practice (ADAPT) framework for adapting and implementing a provider-focused intervention to increase the uptake of HPV vaccination in the pediatric oncology setting. Once the rationale and guiding principles for engaging in this process are presented, the intervention adaptation processes are illustrated via descriptions of assessment, planning, piloting, evaluation, implementation, and maintenance. Additional considerations specific to the pediatric oncology setting are also provided. By applying ADAPT or other appropriate frameworks when adapting and implementing pediatric interventions in the cancer survivorship setting, progress will be made toward establishing a gold standard in approaching these tasks. Ultimately, these collective efforts will maximize the likelihood of effective intervention delivery and reduce health risk in this vulnerable population.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 9","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35857","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143883894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concerns regarding stem cell mobilization in liposomal mitoxantrone therapy for relapsed/refractory T-cell/natural killer-cell lymphomas","authors":"Xia Zhao MD,&nbsp;Zhihe Liu MD","doi":"10.1002/cncr.35848","DOIUrl":"https://doi.org/10.1002/cncr.35848","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 9","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143883895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to “Concerns regarding stem cell mobilization in liposomal mitoxantrone therapy for relapsed/refractory T-cell/natural killer-cell lymphomas”","authors":"Yan Gao MD,&nbsp;Hui-Qiang Huang MD","doi":"10.1002/cncr.35847","DOIUrl":"https://doi.org/10.1002/cncr.35847","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 9","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143883891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calcium may help to protect against colorectal cancer","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.35827","DOIUrl":"https://doi.org/10.1002/cncr.35827","url":null,"abstract":"&lt;p&gt;Dairy products, largely or entirely because of calcium, help to protect against colorectal cancer according to the authors of a recent study.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;“This is the most comprehensive single study ever conducted into the relationship between diet and bowel cancer, and it highlights the potential protective role of calcium in the development of bowel cancer,” says the lead author of the study, Keren Papier, PhD, a nutritional epidemiologist in the Cancer Epidemiology Unit of the Nuffield Department of Population Health at the University of Oxford.&lt;/p&gt;&lt;p&gt;The finding adds to the already well-established evidence for positive associations between alcohol use as well as the consumption of red and processed meat and colorectal cancer risk, which also were found in this study.&lt;/p&gt;&lt;p&gt;The study was performed because of the limitations of studies looking more comprehensively at dietary factors and colorectal cancer risk and other limitations such as dietary measure error and small sample sizes.&lt;/p&gt;&lt;p&gt;Using a large prospective study of 542,778 women in the United Kingdom, the investigators performed a systematic analysis that examined 97 dietary factors and the subsequent risk of colorectal cancer. Each participant completed a detailed dietary questionnaire.&lt;/p&gt;&lt;p&gt;Seventeen of the 97 dietary factors assessed were associated with colorectal cancer risk. Among these 17 dietary factors, alcohol and calcium intake had the strongest associations (based on the lowest p value) with colorectal cancer risk, with a positive association for alcohol (relative risk [RR] per 20 g/day, 1.15; 95% confidence interval [CI], 1.09–1.20; &lt;i&gt;p&lt;/i&gt; &lt; .0000001) and an inverse association for calcium (RR per 300 mg/day, 0.83; 95% CI, 0.77–0.89; &lt;i&gt;p&lt;/i&gt; &lt; .000001). Consumption of red meat and processed meat also was positively associated with colorectal cancer risk, with an RR per 30 g/day of 1.08 (95% CI, 1.03–1.12; &lt;i&gt;p&lt;/i&gt; &lt; .01), but the association was not as robust as that for alcohol.&lt;/p&gt;&lt;p&gt;When the researchers looked at types of dairy-related foods and nutrients, an inverse risk association was seen with all dairy-related factors, including dairy milk, yogurt, riboflavin, magnesium, phosphorus, and potassium. The inverse association of these nutrients primarily was due to the calcium associated with these nutrients. Dairy milk in particular was associated with a 14% lower risk per 200 g/day.&lt;/p&gt;&lt;p&gt;These findings were not changed when the researchers adjusted for potential lifestyle factors, with alcohol, calcium, and dairy milk remaining significantly associated with colorectal risk. An independent look at the association of calcium with colorectal cancer risk and dairy milk with that risk showed calcium, but not dairy milk, to be independently associated with colorectal cancer risk.&lt;/p&gt;&lt;p&gt;Investigators also found an inverse risk association with other foods and nutrients, including breakfast cereal, fruit, whole grains, carbohydrates, fiber","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 9","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35827","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143883898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Cancer Statistics, 2025” provides data on cancer occurrence and outcomes","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.35826","DOIUrl":"https://doi.org/10.1002/cncr.35826","url":null,"abstract":"&lt;p&gt;Every year, the American Cancer Society publishes a report on the estimated new cancer cases and deaths in the United States. The good news is that the cancer mortality rate continued to decline through 2022. Since 1991, cancer mortality has dropped by 34%; this represents an estimated 4.5 million fewer people dying of the disease. Much of this can be attributed to the prevention of smoking-related cancers, such as lung cancer, through smoking reduction and cessation. Earlier detection through screening also has contributed to the mortality reduction via preventative measures such as the removal of precancerous lesions in the cervix and colorectum and earlier detection of prostate, lung, and breast cancers. Other good news is the ongoing progress in the development of newer treatments, including more targeted therapies and immunotherapies for many cancers and optimization of established therapies.&lt;/p&gt;&lt;p&gt;However, the progress is uneven, with not all populations benefitting equally. Moreover, the incidence of many common cancers is increasing with a disproportionate impact on women, which is shifting the burden.&lt;/p&gt;&lt;p&gt;Here are a few key highlights of this year’s state of cancer as detailed in “Cancer Statistics, 2025.”&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; As in previous years, population-based data came from the National Cancer Institute’s Surveillance, Epidemiology, and End Results program and the Centers for Disease Control and Prevention’s National Program of Cancer Registries and were compiled by the North American Association of Central Cancer Registries (for incidence data) and by the National Center for Health Statistics (for mortality data).&lt;/p&gt;&lt;p&gt;In total, 2,041,910 new cancer diagnoses are expected in 2025; this represents approximately 5600 cases every day. For men, the total number of estimated new cancer cases in 2025 for all sites is 1,053,250, with prostate, lung/bronchus, and colorectal cancer accounting for nearly half (48%) of all diagnoses. Prostate cancer is the most common and accounts for 30% of all new cancers in men. For women, the total number of estimated new cancer cases in 2025 for all sites is 988,660, with breast, lung, and colorectal cancer accounting for 51% of all new cases. Breast cancer remains the most common and accounts for 32% of new cancers in women.&lt;/p&gt;&lt;p&gt;One key new finding in the report is that the cancer burden is shifting toward women and younger adults. For men, the incidence of new cancers, primarily driven by prostate cancer, declined steeply between 2007 and 2013 and was stable through 2021. For women, however, cancer incidence gradually rose from a low of 361.2 per 100,000 in 1978 to 443.2 in 2021; this reflects an overall increase of 23%. The declining incidence in men along with this increasing incidence in women narrowed the male-to-female rate ratio to 1.1 in 2021 from its earlier peak in 1992 of 1.6. For women aged 50–64 years, the incidence rate surpassed that of men in 2021, although the rates are sti","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 9","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35826","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143883892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}